0
0
Recent research underscores the significant cancer risks that BRCA1 and BRCA2 genetic mutations pose to men, advocating for expanded national screening guidelines to include genetic testing for males. Traditionally associated with breast and ovarian cancers in women, these mutations also increase the risk of several cancers in men, including prostate, pancreatic, and breast cancers.
A review article published in JAMA Oncology by experts from the Fred Hutch Cancer Center and the University of Washington highlights the need for increased awareness and testing. Heather Cheng, director of the Fred Hutch’s Prostate Cancer Genetics Clinic, emphasized that men are under-tested for BRCA1 and BRCA2 gene variants. “Men often get tested for their daughters, but don’t always recognize the importance for their own health,” Cheng remarked.
The review details updated screening and treatment guidelines for men carrying harmful BRCA1 and BRCA2 mutations. Despite men constituting 50% of all BRCA1/2 mutation carriers, their testing rate is merely one-tenth of that for women. This disparity in testing rates can delay crucial early detection and treatment.
The updated guidelines recommend that men discuss their family’s cancer history with healthcare providers to assess their own risk. Cheng believes that by increasing genetic screening among men, the medical community can enhance research efforts, improve early detection, and ultimately reduce the overall burden of BRCA-related cancers.
In summary, the growing body of research calls for a paradigm shift in the screening approach for BRCA gene mutations. By incorporating men into the genetic testing framework, healthcare providers can better manage and mitigate the risks associated with these genetic variants, benefiting both men and their families.
